DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Meta Expands AI Training With Employee Activity Tracking Tools 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
NEW YORK, March 03, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Arizona on behalf of investors who purchased INSYS Therapeutics, Inc. (NASDAQ:INSY) securities between March 3, 2015 and January 25, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/insys-therapeutics-inc. There is no cost or obligation to you.
The complaint alleges that INSYS made materially false and misleading statements to investors and/or failed to disclose that: (i) the Company was engaged in the illegal and improper off-labeling marketing of Subsys, a cancer pain treatment; (ii) certain INSYS employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (iii) as a result, the Company’s financial statements were materially false and misleading at all relevant times.
On January 25, 2016, the Southern Investigating Report Foundation published an article entitled “The Brotherhood of Thieves: Insys Therapeutics,” alleging that INSYS pressured employees to develop new schemes to promote the illegal and inappropriate off-label use and sale of Subsys.
If you suffered a loss in INSYS you have until April 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/insys-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
